- $541.79m
- $568.63m
- $170.44m
U.S. STOCKS ON THE MOVE-Teladoc Health, Mustang Bio, Instacart
U.S. STOCKS ON THE MOVE-B Riley, H&E Equipment, Emergent BioSolutions
Brief: REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
U.S. STOCKS ON THE MOVE-Regenxbio, Danaher, Applied Digital
Regenxbio rises on partnership with Japan's Nippon Shinyaku
U.S. RESEARCH ROUNDUP- Equifax, Microstrategy, Netflix
Brief: Regenxbio Initiates Pivotal Phase Of Affinity Duchenne Trial Of Rgx-202 Gene Therapy
Regenxbio Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Regenxbio Announces Positive Data From Pivotal Dose Level Of Rgx-121 Demonstrating Long-Term Systemic Effect
Brief: Regenxbio Announces New Positive Data From Affinity Duchenne Trial Of RGX-202
Brief: Regenxbio Announces Expansion Of Affinity Duchenne Trial
Sarepta surges as investors cheer expanded use of gene therapy (updated)
Sarepta surges as investors cheer expanded use of gene therapy
Brief: REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
U.S. STOCKS ON THE MOVE-Tesla, Casey's General Store, Western Alliance
U.S. STOCKS ON THE MOVE-Tesla, Take-Two, Caterpillar
U.S. STOCKS ON THE MOVE-Oracle, Beamr Imaging, Casey's General Stores
Regenxbio rises after COO promoted to top job
Regenxbio Inc expected to post a loss of $1.26 a share - Earnings Preview